Unveiling The Potential Of Istaroxime W/ Windtree Therapeutics' SEISMiC Extension Study
- 6 months ago
Craig Fraser, CEO of Windtree Therapeutics, Inc., was recently interviewed by Benzinga.
Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.
Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with the ability to activate SERCA2a, which is critical in patients experiencing acute cardiac events. Its lead candidate, istaroxime, is being developed as a first-in-class treatment for cardiogenic shock and acute heart failure.
Mr. Frasier discussed his company’s recent deal with Lee’s Pharmaceuticals which will help Windtree to develop and commercialize its therapies.
Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.
Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with the ability to activate SERCA2a, which is critical in patients experiencing acute cardiac events. Its lead candidate, istaroxime, is being developed as a first-in-class treatment for cardiogenic shock and acute heart failure.
Mr. Frasier discussed his company’s recent deal with Lee’s Pharmaceuticals which will help Windtree to develop and commercialize its therapies.